BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Boundless Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31−0.03 (-1.28%)
Close on Oct 19, 2026
- Market cap
- $51.86M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.94 (+68.61%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $51.86M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- –
- Free cash flow yield
- -109.40%
Fundamentals
- Net income
- -$64.01M
- EPS, diluted
- -$2.86
- Free cash flow
- -$56.73M
- Book value per share
- $2.94
- Diluted shares
- 22M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$68.01M
Net income
-$64.01M
EPS, diluted
-$2.86
Free cash flow
-$56.73M
Reported periodTrailing twelve months